Chimerix

Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox. The company was founded by George R. Painter, III and Timothy Wollaeger in April 2000 and is headquartered in Durham, NC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Chimerix transitions successfully, eyes oncology pipeline growth

Chimerix navigated a key transition in 2022, focusing on oncology pipeline
Financially, the company aims to fund operations into 2027
Promising clinical data on ONC201 and ONC206 highlight potential market opportunities

Chimerix reports operational and financial progress, poised for oncology growth

Chimerix demonstrated operational and financial progress in Q1 2023, with a strong focus on advancing its oncology pipeline and addressing analyst inquiries.
The company's innovative research capabilities, promising drug candidates, and solid financial position position it well for future growth and success.

Chimerix reports robust Q2 performance and strategic leadership recruitment

Chimerix's strong performance in global engagement and dose escalation studies positions them well for future growth in targeted oncology.
Maintaining financial discipline and leadership recruitment indicate a strategic approach to capital allocation and pipeline expansion.
Clear evaluation criteria and data sharing timelines will be crucial for addressing challenges and seizing opportunities in advancing their programs.

Chimerix (CMRX) advances oncology studies, poised for commercialization success

Chimerix (CMRX) showcased progress in ONC201 and ONC206 studies, with a focus on scientific validation and commercialization readiness.
Financially stable with a cash balance of $217 million, the company is well-positioned for future growth and operational sustainability.
Engagement with the medical community and strategic planning for market entry highlight Chimerix's commitment to innovation and patient care.

Chimerix reports disciplined finances, positive trial results, eyes global expansion

Chimerix showcased financial discipline amidst a net loss, while emphasizing positive Phase II results of ONC201. The company is focused on advancing the Phase III ACTION study with global enrollment and strategic management appointments. Challenges include timely execution of the study and managing enrollment trends, with opportunities in commercialization and partnerships.

Chimerix reports robust Q1 earnings, eyes global drug approvals

Chimerix's Q1 2024 earnings call highlighted strong financials, progress in key studies, and strategic growth initiatives. While facing challenges in enrollment, regulatory pathways, and commercialization, the company remains optimistic about its pipeline and financial discipline.

Chimerix advances key studies, maintains strong finances amid challenges

Chimerix (CMRX) demonstrated progress in key clinical studies and maintained a strong financial position in Q2 2024.
While facing challenges with increased R&D expenses and a net loss, the company is strategically investing in growth opportunities.
Opportunities lie in potential drug registrations, intensified dosing schedules, and investments in launch readiness for future success.
Overall, Chimerix remains focused on advancing its pipeline and financial strategy to drive long-term value for stakeholders.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox. The company was founded in April 2000 and is headquartered in Durham, NC.

Chimerix (CMRX) delivered earnings and revenue surprises of -13.33% and -17.27%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Chimerix (CMRX) Reports Q1 Loss, Lags Revenue Estimates

Shares of Chimerix (NASDAQ:CMRX) were unchanged at $2.52 after the company reported Q1 results.

Recap: Chimerix Q1 Earnings

FDA Clearance to Proceed with Phase 2/3 Randomized, Double-Blind, Placebo Controlled Study

Chimerix Announces Initiation of a Phase 2/3 Study of DSTAT in Acute Lung Injury for Patients with Severe COVID-19

DURHAM, N.C., April  28, 2020  (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that the Company has received clearance from the U.S. Food and Drug Administration (FDA) for a rolling submission of its New Drug Application (NDA) for the approval of brincidofovir (BCV) as a medical countermeasure for smallpox. The Company intends to begin the rolling NDA submission for BCV in May 2020 with completion targeted for mid-2020. Chimerix is developing BCV as a potential medical countermeasure for smallpox under an ongoing collaboration and funding provided by the Biomedical Advanced Research and Development Authority (BARDA), part of the office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services, under ongoing USG Contract No HHSO10201100013C.

Chimerix Receives FDA Clearance for Rolling Submission of New Drug Application for Brincidofovir as a Medical Countermeasure for Smallpox

Chimerix (CMRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

All You Need to Know About Chimerix (CMRX) Rating Upgrade to Buy

Chimerix, Inc. (CMRX) CEO Mike Sherman on Q4 2019 Results - Earnings Call Transcript

Brincidofovir demonstrated a statistically significant survival advantage in two well-characterized animal models of lethal orthopoxvirus infection Brincidofovir demonstrated a statistically significant survival advantage in two well-characterized animal models of lethal orthopoxvirus infection

Chimerix Presents Data Supporting Brincidofovir as a Potential Treatment for Smallpox at 2020 American Society for Microbiology Biothreats Meeting

Is  (CMRX) Outperforming Other Medical Stocks This Year?

Has Chimerix (CMRX) Outpaced Other Medical Stocks This Year?

DURHAM, N.C., Dec.  10, 2019  (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq: CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that data relating to its dociparstat sodium (DSTAT) program, formerly known as CX-01, were presented at the 61st American Society of Hematology Annual Meeting, in Orlando, FL.

Chimerix Presents Updated Results from Phase 2 Clinical Trial of DSTAT in Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia at American Society of Hematology Annual Meeting

Chimerix's (CMRX) CEO Michael Sherman on Q3 2019 Results - Earnings Call Transcript

Includes All Human Indications Excluding Prevention and Treatment of Smallpox

Chimerix Announces Exclusive Global License Agreement with SymBio Pharmaceuticals for Brincidofovir

Chimerix (CMRX) delivered earnings and revenue surprises of -105.88% and -37.48%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Chimerix (CMRX) Reports Q2 Loss, Lags Revenue Estimates

Chimerix (CMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Chimerix (CMRX) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

As of late, it has definitely been a great time to be an investor Chimerix.

Will Chimerix to Surge Higher?

Chimerix's (CMRX) CEO Mark Iwicki on Q1 2019 Results - Earnings Call Transcript

Chimerix (CMRX) delivered earnings and revenue surprises of 0.00% and 17.80%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Chimerix (CMRX) Reports Q1 Loss, Tops Revenue Estimates

Chimerix (CMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Chimerix (CMRX) Report Negative Q1 Earnings? What You Should Know

News of changes to its executive team boosted Chimerix Inc. shares on Tuesday. Specifically, the firm announced the appointment of Michael A. Sherman as chief executive of Chimerix, effective immediately.

News for Chimerix Stock (CMRX)